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Abstract
Background: Inhaled corticosteroids are the recommended first-line treatment for asthma but adherence to
therapy is suboptimal. The objectives of this study were to compare the efficacy and safety of once-daily (OD)
evening and twice-daily (BD) regimens of the novel inhaled corticosteroid fluticasone furoate (FF) in asthma
patients.
Methods: Patients with moderate asthma (age ≥ 12 years; pre-bronchodilator forced expiratory volume in 1
second (FEV1) 40-85% predicted; FEV1 reversibility of ≥ 12% and ≥ 200 ml) were randomized to FF or fluticasone
propionate (FP) regimens in a double-blind, crossover study. Patients were not permitted to have used any ICS for
≥ 8 weeks prior to enrolment and subsequently received doses of FF or FP 200 μg OD, FF or FP 100 μg BD and
matching placebo by inhalation for 28 days each. Primary endpoint was Day 28 evening pre-dose (trough) FEV1;
non-inferiority of FF 200 μg OD and FF 100 μg BD was assessed, as was superiority of all active treatment relative
to placebo. Adverse events (AEs) and 24-hour urinary cortisol excretion were assessed.
Results: The intent-to-treat population comprised 147 (FF) and 43 (FP) patients. On Day 28, pre-dose FEV1 showed
FF 200 μg OD to be non-inferior (pre-defined limit -110 ml) to FF 100 μg BD (mean treatment difference 11 ml;
95% CI: -35 to +56 ml); all FF and FP regimens were significantly superior to placebo (p ≤ 0.02). AEs were similar to
placebo; no serious AEs were reported. Urinary cortisol excretion at Day 28 for FF was lower than placebo (ratios:
200 μg OD, 0.75; 100 μg BD, 0.84; p ≤ 0.02).
Conclusions: FF 200 μg OD in the evening is an efficacious and well tolerated treatment for asthma patients and
is not inferior to the same total BD dose.
Trial registration: Clinicaltrials.gov; NCT00766090.
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Background
A variety of treatments are available for asthma but
there remains potential to improve the level of disease
control in adults and children [1-4]. Failure to achieve
asthma control affects patients’ daily lives, for example
through persistent symptoms, more frequent exacerba-
tions and missed work and school time, placing
demands on emergency care facilities [2,5]. Further
improvements to the range of therapeutic options for
asthma are needed so that patients can achieve better
disease control.
Inhaled corticosteroids (ICS) are the most effective
controller medications for the first-line treatment of
asthma in adults and children and are also used at later
stages in combination with other medications, specifically
long-acting beta2 agonists (LABA) [6]. ICS are typically
developed for twice-daily dosing but once-daily evening
dosing of an ICS has been reported to significantly
improve adherence to therapy compared with twice-daily
dosing (93.3% vs. 89.3% [p < 0.001] as measured by auto-
matic dose counter) in an open-label 12 week study of
mometasone furoate [7]. This is a benefit that has the
potential to improve patient outcomes, given the associa-
tion between poor adherence rates (particularly for con-
troller medications) and uncontrolled asthma in children
* Correspondence: ashley.woodcock@manchester.ac.uk
1School of Translational Medicine, University of Manchester, Manchester, UK
Full list of author information is available at the end of the article
Woodcock et al. Respiratory Research 2011, 12:160
http://respiratory-research.com/content/12/1/160
© 2011 Woodcock et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.and adults [8,9], and the reported correlation between
falling rates of adherence to ICS and higher rates of
asthma-related hospitalization in adults [10].
Animal and human pharmacology studies show that
the novel ICS fluticasone furoate (FF) has a long dura-
tion of action and prolonged retention in the lung, sug-
g e s t i n gt h a ti ti ss u i t a b l ef o ronce-daily dosing [11]. FF
and fluticasone propionate (FP) are structurally different.
At the C-17a p o s i t i o n ,F Fc o n t a i n sa ne s t e rd e r i v e d
from 2-furoic acid which replaces the simpler propio-
nate ester. These differences mean that FF has more
complete occupancy of the 17a pocket in the glucocor-
ticoid receptor [12] and higher glucocorticoid receptor
binding affinity than FP [13]. As part of the overall
phase II development plan investigating FF, dose-ran-
ging studies in asthma patients have demonstrated that
FF has a favourable efficacy and safety profile when
administered once-daily in the evening [14-16].
The aims of the current study were to compare the
efficacy and safety of once-daily versus twice-daily FF
regimens with each other and with placebo in patients
uncontrolled on a non-corticosteroid controller or
short-acting beta2 agonist (SABA) alone. The study spe-
cifically tested the hypothesis that a once-daily regimen
is not inferior to a twice-daily regimen with respect to
lung function (evening pre-dose forced expiratory
volume in 1 second (FEV1)) after 4 weeks’ treatment. FP
once-daily and twice-daily regimens were included as
active controls to confirm that the primary efficacy vari-
able of trough FEV1 (measured pre-dose in the evening)
o nD a y2 8w a ss e n s i t i v ee n o u g ht od e t e c td i f f e r e n c e s
between active treatments and placebo.
Methods
Study design
This was a randomized, placebo-controlled crossover
study designed to compare the efficacy and safety of 28
days’ treatment of FF given as a once-daily and twice-
daily regimen in adolescents and adults with asthma.
The study was approved by local ethics review commit-
tees and was conducted in accordance with the Declara-
tion of Helsinki and Good Clinical Practice guidelines at
16 investigative sites in the USA between October 2008
and March 2009. All patients gave written informed
consent. The trial is registered as NCT00766090 on the
Clinicaltrials.gov registry and the sponsors’ study num-
ber is FFA112202.
Patients
Patients with moderate persistent asthma, aged 12 years
or more with a pre-bronchodilator FEV1 of 40-85% of
predicted normal value and reversibility of FEV1 to
inhaled salbutamol of at least 12% and at least 200 ml
were eligible for inclusion [17]. Patients were taking
SABA and had not taken ICS for ≥ 8 weeks, but could
have taken LABAs, xanthines, cromones, or leukotriene
modifiers provided they had been stopped at screening.
Patients had to refrain from using oral, parenteral, and
depot forms of corticosteroids in the 8 weeks before
screening and anti-IgE therapy in the 12 weeks before
screening. We excluded patients who had smoked in the
year before the study, those with a smoking history of >
10 pack-years, and individualsw i t har e s p i r a t o r yi n f e c -
tion, life-threatening asthma, or asthma exacerbations
requiring either hospitalization in the 6 months before
screening or oral corticosteroids in the 8 weeks before
screening. Drug therapy was withheld for baseline spiro-
metry, treatment with LABAs and leukotriene modifiers
was ceased the day before assessment, and patients
could not take salbutamol during the 6-hour period
before the clinic visit.
Randomization
Eligible patients entered a run-in period of at least 7
days during which safety evaluations were conducted
including a 24-hour urine collection for determination
of cortisol excretion (see below). Patients were randomly
assigned to either an FF group or an FP group, in a 7:2
ratio, respectively. To be eligible to enter the treatment
period patients were required, at the end of the run-in
period to exhibit the following; (I) evening FEV1
between 40% and < 80% and at least one of a daily
symptom score of ≥ 1, rescue medication use on 4 of
the last 7 days or PEF variability of ≥ 20% on 4 of the
last 7 days; (2) evening FEV1 between ≥ 80% and 85%
and at least one of a daily symptom score of ≥ 1, rescue
medication use on all of the last 7 days or PEF variabil-
ity of ≥ 20% on all of the last 7 days. Additionally
patients were required to have a 24-hour urine cortisol
sample available at the end of the run-in period. In the
FF group all patients received drug via the NDPI and in
the FP group via the Diskus™; thus although patients
and investigators were blinded to which treatment they
were receiving within a group, they were not blinded to
whether they were allocated to an FF or an FP group.
The central randomization schedule was generated by
the sponsor using a validated computerized system
(RandAll). The Registration and Medication Ordering
System (RAMOS), an automated, interactive telephone
based system, was used by the investigator or designee
to register and randomize the patient and receive medi-
cation assignment information. Treatment assignment
could be unblinded only in an emergency, through a call
to the interactive telephone system.
Treatments
Patients were assigned to 1 of 12 possible treatment
sequences (table 1), each sequence comprising three 28-
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periods. Six sequences contained FF 200 μg once daily
in the evening (with placebo in the morning), FF 100 μg
twice daily and matching placebo twice daily dosed from
a novel dry powder inhaler. Six sequences contained FP
200 μg once daily in the evening (with placebo in the
morning), FP 100 μg twice daily and matching placebo
twice daily dosed from a Diskus™ inhaler. The differ-
ence between the delivery devices used to deliver FF
and FP meant that investigators could distinguish
whether patients were assigned to an FF or FP sequence,
but were double-blind to whether placebo or either of
the two active regimens were being administered.
From the screening visit onwards, no additional
asthma medications were allowed except for rescue sal-
butamol. Intranasal and topical corticosteroids, and oral,
ocular, and intra-nasal antihistamines were permitted.
Outcome measurements
The primary endpoint was the pre-dose, pre-rescue
bronchodilator FEV1 on the evening of Day 28 of the
treatment period. The protocol required that spirometry
was performed on Days 0 and 28 at 8.00 pm +/- 3
hours, at least 6 hours after the last administration of
salbutamol and within 1 hour of the time of the Day 0
measurement.
Safety evaluation
Adverse events (AEs) were coded using Medical Dic-
tionary for Regulatory Activities (MedDRA, version 11).
Safety assessments included routine laboratory tests,
vital signs and oropharyngeal examination, and change
in 24-hour urinary cortisol (UC) excretion between
study baseline and the end of each 28-day treatment
period. Patients who had asthma exacerbations (defined
as any worsening of asthma that required emergency
intervention, hospitalization, or treatment with an
asthma medication not allowed by the study protocol)
were withdrawn from the study.
Statistical analysis
The intent-to-treat (ITT) population comprised all
patients who received at least one dose of study medica-
tion; the per-protocol (PP) population was the subset of
patients in the ITT population who completed at least
one treatment period without a protocol deviation. Both
populations were used to assess the primary comparison
of FF once daily versus FF twice daily. For the assess-
ment of differences between active and placebo groups,
the ITT population was used. The PP population was
considered to be a supportive analysis. The UC popula-
tion consisted of patients who had urine samples with
no confounding factors that would limit the analysis of
UC.
Assuming an average within-patient standard devia-
tion in pre-bronchodilator evening trough FEV1 of 210
ml and a non-inferiority limit of -110 ml, 84 completed
patients would be required in the FF patient set to
demonstrate non-inferiority of FF 200 μgo n c ed a i l y
relative to FF 100 μg twice daily with 92% statistical
power and a 2.5% one-sided significance level. For the
superiority comparisons with placebo, this number of
patients would enable detection of a difference of 200
ml between each of the FF groups and placebo with >
99% power. For the FP patient set, the target number of
completed patients (n = 24) would enable detection of a
200 ml difference between FP dosed once daily or twice
daily and placebo with 91% power, based on a 2-sided
5% significance level and a within-subject standard
deviation of 210 ml.
Table 1 Distribution of patients between treatment sequences
Sequence Allocation ratio Treatments Delivery device
Period 1 Period 2 Period 3
1 7 Placebo FF 200 μg OD FF 100 μg BD Novel dry powder inhaler
2 7 Placebo FF 100 μg BD FF 200 μgO D
3 7 FF 100 μg BD Placebo FF 200 μgO D
4 7 FF 100 μg BD FF 200 μg OD Placebo
5 7 FF 200 μg OD Placebo FF 100 μgB D
6 7 FF 200 μg OD FF 100 μg BD Placebo
7 2 Placebo FP 200 μg OD FP 100 μg BD Diskus™ inhaler
8 2 Placebo FP 100 μg BD FP 200 μgO D
9 2 FP 100 μg BD Placebo FP 200 μgO D
10 2 FP 100 μg BD FP 200 μg OD Placebo
11 2 FP 200 μg OD Placebo FP 100 μgB D
12 2 FP 200 μg OD FP 100 μg BD Placebo
FF = fluticasone furoate; FP = fluticasone propionate; BD = twice daily;
OD = once daily.
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ment differences was performed using mixed model
analysis of covariance (ANCOVA) with fixed effects for
treatment, period, sex, and age and including period
baseline as part of a bivariate response. In this analysis,
ANCOVA was also used to compare treatment differ-
ences in UC excretion, with treatment, period, age, sex,
and study baseline as fixed effects and patient as a ran-
dom effect. For each treatment group, least square (LS)
mean values were calculated for absolute pre-dose FEV1
a n dc h a n g ei np r e - d o s eF E V 1 from period baseline. All
analyses were pre-planned before the study blind was
broken. No subgroup analyses were performed.
Results
Study population
Of 190 patients randomly assigned to study treatment,
147 were assigned to one of the six FF sequences and
43 to one of the six FP sequences; 134 and 41 patients,
respectively, completed the study. Reasons for failure at
the screening stage and reasons for withdrawal after the
randomization stage are shown in Figure 1. The ITT
population consists of all 190 patients who were rando-
mized and 177 patients met the criteria to be included
in the PP population. Baseline demographic and clinical
characteristics of patients assigned to the two sets of
treatment sequences (FF and FP) are shown in table 2.
Asthma was generally long-standing with 164 patients
(86%) having asthma for at least 5 years.
Efficacy
The mean values of pre-dose FEV1 on Day 28 in each
treatment group and the mean changes compared with
period baseline (Day 0) are shown in table 3 for both
ITT and PP populations. Pre-dose FEV1 increased in all
groups, but the mean increases in the four active treat-
ment groups were approximately twice those in the pla-
cebo group. The differences versus placebo were
statistically significant in all four active treatment
groups, as assessed in the ITT population. For FF 200
μg once daily, FF 100 μg twice daily and FP 100 μg
twice daily, the p value for the difference was < 0.001,
while for FP 200 μg once daily the p value for the differ-
ence was 0.02.
In the ITT population, the lower 95% confidence
interval (CI) for the mean difference between FF 200 μg
once daily and FF 100 μg twice daily in pre-dose FEV1
on Day 28 was -35 ml (LS mean difference of 11 ml)
(table 3; Figure 2). This difference was within the pre-
defined limit of -110 ml, thus demonstrating non-infer-
iority of the FF 200 μg once-daily regimen. Similar
results were obtained from the non-inferiority analysis
in the PP population: the lower 95% CI for the treat-
ment difference was -49 ml (LS mean difference 0 ml).
Data from patients treated with FP indicated numeri-
cally reduced improvement in pre-dose FEV1 with the
200 μg once-daily dose in comparison with 100 μg twice
daily, although no statistical comparison of these groups
was performed.
327 Screened
190 Randomly allocated to one of two treatment sequences
137  Not randomized
   110  Failed inclusion/exclusion criteria
    13  Failed randomization criteria
   6  Study  closed
   5  Withdrew  consent
   2  Investigator  decision
    1  Lost to follow-up
147 FF 200 µg OD, 100 µg BD
 and matching placebo
134 Completed
43 FP 200 µg OD, 100 µg BD
  and matching placebo
2 Withdrawn
   1 Lack of efficacy
   1 Lost to follow-up
13 Withdrawn
   5  Lack of efficacy
   3  Lost to follow-up
   2  Withdrew  consent
   2  Protocol  deviation
   1  Investigator  decision
41 Completed
Figure 1 Disposition of patients. BD = twice daily; OD = twice
daily.
Table 2 Baseline characteristics of patients in each set of
treatment sequences
FF
sequences
(n = 147)
FP
sequences
(n = 43)
Total
(n = 190)
Age (years) 31.4 (15.30) 35.2 (16.03) 32.3 (15.51)
Range 12-68 12-76 12-76
Females, n (%) 87 (59) 21 (49) 108 (57)
Race (%)
White 90 (61) 22 (51) 112 (59)
African American/
African heritage
50 (34) 20 (47) 70 (37)
Other 7 (5) 1 (2) 8 (4)
History of atopy, n (%) 93 (63) 27 (63) 120 (63)
Lung function at screening
Reversibility of FEV1 (%) 27.20
(13.667)
27.52
(16.449)
27.27
(14.298)
Reversibility of FEV1
(ml)
608.2
(304.64)
591.4
(367.47)
604.4
(318.98)
Lung function at study
baseline
Pre-bronchodilator FEV1
(L)
2.296
(0.6176)
2.293
(0.6990)
2.296
(0.6350)
Pre-bronchodilator FEV1
(% predicted)
69.85 (9.704) 67.73
(11.204)
69.37
(10.071)
Values are mean and standard deviation unless stated. Data shown are for the
ITT population.
FEV1 = forced expiratory volume in 1 second; FF = fluticasone furoate;
FP = fluticasone propionate
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No serious AEs were reported and no AEs led to perma-
nent discontinuation of drug or to patient withdrawal.
The frequency of on-treatment AEs was higher in the
FF 200 μg once-daily, FF 100 μg twice-daily and placebo
NDPI groups (16%, 18%, and 14%, respectively) than in
the FP 200 μg once-daily, FP 100 μg twice-daily and
Diskus™ placebo groups (5%, 7% and 12% respectively).
Upper respiratory tract infections (URTI) were the most
commonly reported AEs, occurring in 5% of patients in
each of the FF groups and 1% in the placebo group; no
other AEs were reported by more than 1% of patients in
either of the FF groups or the placebo group during the
treatment period (table 4). However, only three of the
AEs reported (headache/dry throat, FF 100 μgt w i c e
daily; tachycardia, FP 200 μgo n c ed a i l y )w e r ec o n s i d -
ered to be potentially drug-related. One patient reported
dysphonia (FP 200 μg once daily), but there were no
cases of oral candidiasis.
Asthma exacerbations occurred in five (3%) patients
on placebo, and one (< 1%) patient on FF 200 μgo n c e
daily. None of the exacerbations were severe enough to
require hospitalization.
UC excretion data were analyzed in 170 patients with
adequate 24-hour collections at study baseline and Day
28. The Day 28 ratio to placebo was statistically signifi-
cantly lower in the FF 200 μg once-daily and FF 100 μg
twice-daily arms (ratio 0.75, p < 0.001 and 0.84, p =
0.020, respectively), but the ratios with FP were not sta-
tistically significant for the FP 200 μg once-daily and FP
100 μg twice-daily arms (ratio 1.03, p = 0.808 and 0.89,
p = 0.338, respectively) (Figure 3). No AEs associated
with abnormal urinary-free cortisol were reported.
There were no clinically important changes in any
laboratory test parameter or vital signs with any study
treatment during any of the treatment periods.
Discussion
In this crossover study in adolescents and adults with
moderate asthma, the same d a i l yd o s eo fan o v e lI C S ,
FF, administered once daily in the evening or as a twice-
daily regimen was compared over a 28-day treatment
period. For the primary efficacy variable of evening pre-
dose FEV1, FF 200 μg once daily in the evening was
non-inferior to FF 100 μg twice daily. All four active
treatment arms were associated with significantly higher
pre-dose FEV1 values than placebo. With FP, a numeri-
cally higher increase in pre-dose FEV1 with twice-daily
dosing than with once-daily dosing was observed. The
Table 3 Evening pre-dose FEV1 on Day 28 of treatment and improvement from period baseline for each treatment
regimen (all placebo treatments were pooled for these analyses)
Placebo FF 200 μg OD FF 100 μg BD FP 200 μg OD FP 100 μgB D
Number of patients 187 140 142 42 43
LS mean, ml (SE) 2605
(43.4)
2714
(44.4)
2703
(44.3)
2693
(53.5)
2737
(53.3)
LS mean change from period baseline, ml (SE) 112
(18.6)
221
(20.9)
210
(20.7)
199
(36.5)
244
(36.1)
LS mean difference
(active-placebo), ml
(95% CI)
NA 108
(64-153);
p < 0.001
98
(54-142);
p < 0.001
87
(14-161);
p = 0.020
132
(59-205);
p < 0.001
LS mean difference
(FF 200 μg OD-FF 100 μg BD), ml
(95% CI)
NA 11
(-35-56);
p = 0.641
NA NA NA
Absolute values and all differences are LS means, with 95% CI for non-inferiority and p values for superiority analysis for all comparisons between treatments.
Data shown are for the ITT population.
BD = twice daily; CI = confidence interval; FF = fluticasone furoate;
FP = fluticasone propionate; LS = least square, NA = not applicable; OD = once daily; SE = standard error
FP 100 µg BD – placebo
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Figure 2 Mean treatment difference (and 95% CI) adjusted for
treatment, period, sex and age, for comparisons between
active treatments and placebo and between the two FF
dosage regimens (ITT population). Dotted line at 0 shows the
point at which the two interventions would have an equal
effect on pre-dose FEV1. The lower dotted line (for the FF 200
μg OD vs. FF 100 μg BD comparison) shows the predefined
-110 ml threshold for non-inferiority of FF 200 μg OD versus
FF 100 μgB D . BD = twice daily; CI = confidence interval; OD =
twice daily; FF = fluticasone furoate; FP = fluticasone propionate
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with differences previously reported for FP once versus
twice daily [18,19], although this supports the current
indication for twice-daily dosing of FP in asthma the
study was not powered nor designed to assess differ-
ences between once-daily and twice-daily dosing of FP,
only to assess differences between either FP dosing regi-
men and placebo. FF appears to be suitable for once-
daily dosing as both once-daily and twice-daily dosing
(same total daily dose) produced similar improvements
in lung function,. The efficacy results for FF in the cur-
rent study are consistent with the results of three dose-
ranging studies in patients with different levels of
asthma severity, in which 8 weeks of FF administered
once daily in the evening produced superior
improvements in lung function and symptoms relative
to placebo at doses of 50-800 μg once daily [14-16].
Both regimens of FF were well tolerated in this study
and AE reporting rates were similar to placebo, espe-
cially when considering the AEs reported for placebo
and FF using the NDPI, and placebo and FP using the
Diskus™. It is possibly the case that the higher inci-
dence of AEs reported with the NDPI regardless of
treatment (placebo or FF) resulted from a lack of famil-
iarity with the device. There was only one asthma
exacerbation among patients receiving FF and no dys-
phonia or oropharyngeal candidiasis. URTIs were the
only event to be reported more often in the FF groups
than with placebo, and were not associated with loss of
asthma control. A reduction in UC of 16% and 25%
(relative to placebo) was observed with FF 100 μgB D
and FF 200 μg OD, respectively, and this finding con-
trasts those of other FF dose-ranging studies in which
patients with asthma did not show any UC suppression
relative to placebo after 8 weeks’ treatment at doses up
to 600 μg once daily [14-16]. There was a numerical
reduction in UC of the same magnitude (19%) in the FP
100 μg twice-daily regimen. No adverse safety events
were recorded in the current study that could be attrib-
uted to cortisol suppression. Further studies are needed
to assess the magnitude of any potential effect of corti-
sol suppression in susceptible patients.
The crossover design used for the current study had
the advantage of reducing potential variability compared
with a parallel-group design. The study was not comple-
tely double-blind, as the differences in the inhaler
devices used to deliver FF and FP enabled investigators
to distinguish between those two groups. Patients may
also have known whether they received FF or FP, but
they had no involvement or choice in their treatment
sequence or choice of active drug. However, patients
Table 4 Number and proportion of patients reporting AEs during treatment, for events reported by at least 1% of
patients in the FF or placebo arms
Number of patients reporting event, n (%) Placebo
nDPI
(n = 145)
Placebo
DISKUS
(n = 42)
FF
200 μgO D
(n = 140)
FF
100 μg
BD
(n = 142)
FP 200 μgO D
(n = 42)
FP 100 μgB D
(n = 43)
Any on-treatment AE 21 (14) 5 (12) 22 (16) 26 (18) 2 (5) 3 (7)
URTI 2 (1) 0 7 (5) 7 (5) 0 0
Sinusitis 0 1 (2) 1 (< 1) 2 (1) 0 0
Pharyngitis 2 (1) 0 1 (< 1) 0 0 0
Cellulitis 2 (1) 0 0 0 0 0
Tooth infection 0 0 2 (1) 0 0 0
Cough 0 0 0 2 (1) 0 0
Headache 2 (1) 0 2 (1) 0 0 0
Tension headache 0 0 2 (1) 0 0 0
Data shown are for the ITT population.
AE = adverse events; BD = twice daily; FF = fluticasone furoate; OD = once daily; URTI = upper respiratory tract infections.
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Figure 3 Treatment differences for 24-hour urinary cortisol
excretion on Day 28 of treatment, expressed as the adjusted
ratio (active:placebo) of the absolute excretion values (UC
population). BD = twice daily; CI = confidence interval; OD = twice
daily; FF = fluticasone furoate; FP = fluticasone propionate
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the study and no formal statistical comparisons were
made between FF and FP. Given the considerations of
trial practicality, we believe that the 2-week washout per-
iod between treatments was adequate for lung function
and UC to return to baseline; this is consistent with the
recommended minimum time reported for studies on
ICS treatments [20]. The numbers of patients in the ITT
and PP populations exceeded the numbers stipulated by
the sample size calculation, as a higher than expected
proportion of screened patients met the eligibility criteria
for study treatment. We do not believe the use of differ-
ent devices for FF and FP should be considered as a con-
founder for the main study outcomes, although it could
be considered as a limitation of the study. Furthermore,
trough FEV1 was the sole efficacy endpoint of this study
and as such the non-inferiority of FF 200 μgo n c e - d a i l y
dosing to FF100 μg twice-daily dosing cannot be inferred
for other measures of treatment responsiveness such as
PEFR, symptoms and exacerbations.
A once-daily ICS regimen has the potential to improve
adherence by offering greater convenience while ensur-
ing continuous 24-hour control of inflammation and
symptoms. Lack of adherence to ICS treatment in
asthma patients is a predictor of suboptimal disease
control and poor outcome in children and adults
[8,10,21]. A retrospective study in children and adults
showed that in patients who needed asthma-related
emergency care, persistence with ICS use in the pre-
vious 12 months was low (fewer than three prescriptions
filled), and that despite an increase in the number of
prescriptions dispensed in the month of the emergency
event, dispensing rate returned to the level observed
previously in the second month after the event [22]. In
another retrospective analysis, adolescents/young adults
with mild asthma receiving mometasone furoate once
daily showed better adherence and asthma control than
those receiving other twice-daily ICS treatments [23].
However, while a once-daily regimen is approved for
some agents for maintenance treatment of mild asthma
[6], the recommended dosing frequency for the majority
of ICS and for most patients is twice daily.
The current study used a once-daily evening dose regi-
men. Previous studies have compared evening with morn-
ing dosing for once-daily ICS regimens. In a previous
s t u d yo nF F ,a4 0 0μg once-daily evening dose regimen
had similar efficacy to a 200 μg twice-daily regimen, but
the 400 μg once-daily morning dose, although effective,
was less effective than FF 200 μg twice daily [24]. Data on
other ICS also suggest improved efficacy for evening dos-
ing. Triamcinolone once daily was more effective when
the dose was given in the afternoon than in the morning
[25]. Ciclesonide 200 μg once daily had a significantly
greater improvement from baseline in morning PEFR with
evening compared with morning dosing [26]. Mometasone
furoate 200 μg taken in the evening appeared superior to
morning dosing as measured by change in FEV1,f o r c e d
vital capacity, and PEFR from baseline after 12 weeks
(although formal statistics were not applied) [27]. In con-
trast, there appeared to be no difference between morning
and evening once-daily dosing for budesonide compared
with twice-daily dosing [28].
Conclusions
In conclusion, four weeks’ treatment with FF given as a
200 μg dose once daily in the evening has superior effi-
cacy and similar tolerability compared with placebo in
patients with moderate asthma, and is non-inferior to a
FF 100 μg twice-daily regimen as measured by pre-dose
FEV1 response. Some cortisol suppression was noted
with FF, although this was not observed in previous stu-
dies that used higher doses of FF and for longer treat-
ment durations. Although confirmatory studies are
required, the data support the use of FF as a once-daily,
evening dosed, treatment in asthma.
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